• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday

    11/3/22 3:01:22 AM ET
    $ARCT
    $BAND
    $BNFT
    $CHGG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $ARCT alert in real time by email

    U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session.

    • Benefitfocus, Inc. (NASDAQ:BNFT) shares jumped 48.2% to settle at $10.36 on Wednesday after the company announced it will be acquired by Voya Financial for $10.50 per share.
    • Bandwidth Inc. (NASDAQ:BAND) climbed 41.6% to close at $17.42 after the company reported better-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance above analyst estimates.
    • Chegg, Inc. (NYSE:CHGG) rose 22% to close at $25.75 after the company reported better-than-expected Q3 results. The company also issued FY22 sales guidance above analyst estimates.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares jumped 18.7% to close at $21.69 after the company announced collaboration with CSL to develop and commercialize self-amplifying mRNA vaccines. Arcturus to receive upfront payment of $200 million.
    • Mercury General Corporation (NYSE:MCY) rose 14.1% to close at $33.06 following strong quarterly earnings.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) gained 12.5% to close at $80.84 after the company reported better-than-expected Q3 EPS and sales results.
    • Li Auto Inc (NASDAQ:LI) climbed 12.1% to settle at $16.32. Li Auto recently reported it delivered 10,052 vehicles in October 2022, up 31.4% year over year.
    • RLX Technology Inc. (NYSE:RLX) surged 11.7% to close at $1.53.
    • Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) gained 11.3% to close at $70.33 after the company reported better-than-expected Q3 EPS and sales results and raised FY22 sales guidance above estimates.
    • United Therapeutics Corporation (NASDAQ:UTHR) climbed 11.1% to close at $253.65 after the company reported better-than-expected Q3 results.
    • Service Corporation International (NYSE:SCI) climbed 10.4% to close at $67.52 after the company reported better-than-expected Q3 EPS and sales results. The company also raised its FY22 EPS guidance above analyst estimates.
    • Zai Lab Limited (NASDAQ:ZLAB) gained 9.6% to close at $27.43.
    • Yum China Holdings, Inc. (NYSE:YUMC) rose 7.6% to close at $46.32 after reporting a rise in Q3 earnings.
    • Inspire Medical Systems, Inc. (NYSE:INSP) gained 7.5% to settle at $206.69 after the company reported better-than-expected Q3 EPS and sales results. The company also raised its FY22 sales guidance above analyst estimates.
    • The New York Times Company (NYSE:NYT) jumped 7.4% to settle at $31.29 after the company reported better-than-expected Q3 adjusted EPS results and issued guidance.
    • Novo Nordisk A/S (NYSE:NVO) rose 6.4% to settle at $113.23 after the company reported Q3 EPS and sales results were higher year over year. The company also raised FY22 operating profit growth guidance.
    • Match Group, Inc. (NASDAQ:MTCH) shares gained 4.2% to close at $45.74 after the company reported better-than-expected Q3 results.
    • Charles River Laboratories International, Inc. (NYSE:CRL) gained 4.1% to close at $215.75 after the company reported better-than-expected Q3 results.
    Get the next $ARCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARCT
    $BAND
    $BNFT
    $CHGG

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    3/26/2026Peer Perform
    Wolfe Research
    Super Micro Computer Inc.
    $SMCI
    3/23/2026$22.00Outperform → Market Perform
    Northland Capital
    Super Micro Computer Inc.
    $SMCI
    3/20/2026Buy → Hold
    Argus
    Super Micro Computer Inc.
    $SMCI
    3/20/2026Market Perform → Market Underperform
    CJS Securities
    Novo Nordisk A/S
    $NVO
    3/18/2026Underperform
    Bernstein
    Novo Nordisk A/S
    $NVO
    3/18/2026$175.00Outperform
    Bernstein
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    3/18/2026$22.00Buy
    B. Riley Securities
    Li Auto Inc.
    $LI
    3/17/2026$19.00Buy → Neutral
    Goldman
    More analyst ratings

    $ARCT
    $BAND
    $BNFT
    $CHGG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

    Nebulized Tyvaso® (treprostinil) Inhalation Solution demonstrated superiority over placebo for the change in absolute forced vital capacity by 130.1 mL and reduced the risk of clinical worsening in patients with idiopathic pulmonary fibrosis, with positive results observed across all subgroups Integrated analyses of TETON-1 and TETON-2 showed statistically significant treatment effects across the primary and most secondary efficacy endpoints, reinforcing the robustness of the clinically meaningful results observed in each of the individual studies Nebulized Tyvaso combines direct lung delivery with multimodal activity across fibrotic, vascular, and inflammatory pathways that are not cur

    3/30/26 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bandwidth Partners with New Agentforce Contact Center

    Bandwidth has partnered to deliver infrastructure for Salesforce's new CRM-native, AI-driven contact center platformRALEIGH, N.C., March 27, 2026 /PRNewswire/ -- Bandwidth Inc. (NASDAQ: BAND), a leading global cloud communications software company, announced it has partnered with the newly launched Agentforce Contact Center. The boundaries between CRM systems, contact centers and agentic AI are beginning to dissolve as enterprises consolidate around unified cloud architectures that connect customer data directly to live engagement. Salesforce's launch of Agentforce Contact Cente

    3/27/26 8:13:00 AM ET
    $BAND
    Computer Software: Prepackaged Software
    Technology

    Li Auto Inc. Announces Put Right Notification for 0.25% Convertible Senior Notes due 2028

    BEIJING, China, March 27, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced that it is notifying holders of its 0.25% Convertible Senior Notes due 2028 (CUSIP No. 50202M AB8) (the "Notes") that pursuant to the Indenture dated as of April 12, 2021 (the "Indenture") relating to the Notes by and between the Company and Deutsche Bank Trust Company Americas, as trustee and paying agent, each holder has the right, at the option of such holder, to require the Company to purchase all of such holder's Notes or any portion of the principal thereof that is equal to US$1,000 principal amount (or a

    3/27/26 6:00:00 AM ET
    $LI
    Auto Manufacturing
    Industrials

    $ARCT
    $BAND
    $BNFT
    $CHGG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Corp Strategy & Develop Laplume Joseph W bought $4,364 worth of shares (25 units at $174.54), increasing direct ownership by 0.09% to 27,448 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    3/4/26 4:39:28 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    PRESIDENT, CEO, EXEC CHAIRMAN Rosensweig Daniel bought $56,360 worth of shares (100,000 units at $0.56), increasing direct ownership by 1% to 7,625,075 units (SEC Form 4)

    4 - CHEGG, INC (0001364954) (Issuer)

    2/18/26 6:30:27 AM ET
    $CHGG
    Other Consumer Services
    Real Estate

    Director Braunegg George Gwyer bought $49,912 worth of shares (552 units at $90.42), increasing direct ownership by 22% to 3,053 units (SEC Form 4)

    4 - MERCURY GENERAL CORP (0000064996) (Issuer)

    12/11/25 4:30:15 PM ET
    $MCY
    Property-Casualty Insurers
    Finance

    $ARCT
    $BAND
    $BNFT
    $CHGG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

    3/8/24 2:00:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $ARCT
    $BAND
    $BNFT
    $CHGG
    SEC Filings

    View All

    SEC Form DEF 14A filed by Charles River Laboratories International Inc.

    DEF 14A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    3/31/26 7:50:58 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form DEFA14A filed by Mercury General Corporation

    DEFA14A - MERCURY GENERAL CORP (0000064996) (Filer)

    3/31/26 7:34:56 AM ET
    $MCY
    Property-Casualty Insurers
    Finance

    SEC Form DEF 14A filed by Mercury General Corporation

    DEF 14A - MERCURY GENERAL CORP (0000064996) (Filer)

    3/31/26 7:33:33 AM ET
    $MCY
    Property-Casualty Insurers
    Finance

    $ARCT
    $BAND
    $BNFT
    $CHGG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rothblatt Martine A

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    3/27/26 4:32:04 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Edgemond James

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    3/27/26 4:31:39 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Huang Duoduo (Howard)

    4 - Yum China Holdings, Inc. (0001673358) (Issuer)

    3/27/26 10:16:05 AM ET
    $YUMC
    Restaurants
    Consumer Discretionary

    $ARCT
    $BAND
    $BNFT
    $CHGG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Novo Nordisk A/S

    Wolfe Research initiated coverage of Novo Nordisk A/S with a rating of Peer Perform

    3/26/26 9:00:52 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Super Micro Computer downgraded by Northland Capital with a new price target

    Northland Capital downgraded Super Micro Computer from Outperform to Market Perform and set a new price target of $22.00

    3/23/26 8:27:58 AM ET
    $SMCI
    Computer Manufacturing
    Technology

    Super Micro Computer downgraded by Argus

    Argus downgraded Super Micro Computer from Buy to Hold

    3/20/26 3:05:11 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $ARCT
    $BAND
    $BNFT
    $CHGG
    Leadership Updates

    Live Leadership Updates

    View All

    Super Micro Computer Announces Resignation of Board Member Yih-Shyan "Wally" Liaw

    DeAnna Luna Appointed Acting Chief Compliance OfficerSAN JOSE, Calif., March 20, 2026 /PRNewswire/ -- Super Micro Computer, Inc. (NASDAQ:SMCI) ("Supermicro" or the "Company") today announced that Yih-Shyan "Wally" Liaw ("Mr. Liaw") has resigned from the Company's Board of Directors, effective immediately. Following Mr. Liaw's resignation, the Company's Board comprises eight directors. There are no changes to the Board's committee structure. The Company also announced today that it has appointed DeAnna Luna as acting Chief Compliance Officer, effective immediately. Ms. Luna brings to this role more than two decades of experience in global trade compliance, governance, highly regulated markets

    3/20/26 4:38:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Charles River Laboratories Announces Executive Appointments

    Glenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles River as Corporate Senior Vice President and Chief Legal Officer Charles River Laboratories International, Inc. (NYSE:CRL) today announced two executive appointments: Glenn G. Coleman has been named the Company's next Chief Financial Officer and Kerry Dailey has been named to the newly-created position of Chief Legal Officer. Birgit Girshick, Corporate Executive Vice President, Chief Operating Officer and incoming Chief Executive Officer, commented, "We are very pleased to welcome Kerry Dailey and Glenn Coleman in two key executive roles, as we stre

    2/18/26 7:01:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ARCT
    $BAND
    $BNFT
    $CHGG
    Financials

    Live finance-specific insights

    View All

    RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results

    SHENZHEN, China, March 13, 2026 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsNet revenues were RMB1,141.3 million (US$163.2 million) in the fourth quarter of 2025, increasing by 40.3% from RMB813.5 million in the same period of 2024.Gross margin was 31.4% in the fourth quarter of 2025, compared with 27.0% in the same period of 2024.Non-GAAP income from operations[1] was RMB158.1 million (US$22.6 million) in the fourth quarter of 2025, increasing by 37.9% from

    3/13/26 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    Li Auto Inc. Announces Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Quarterly total revenues reached RMB28.8 billion (US$4.1 billion)1Quarterly deliveries were 109,194 vehiclesFull year total revenues reached RMB112.3 billion (US$16.1 billion)Full year deliveries were 406,343 vehicles BEIJING, China, March 12, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced its unaudited financial results for the quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter of 2025 and Full Year 2025 Total deliveries for the fourth quarter of 2025 were 109,194 vehicles, representing a 31.2% year-over-year decrease.              FY 2025

    3/12/26 4:30:00 AM ET
    $LI
    Auto Manufacturing
    Industrials

    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

    ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates. "Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical d

    3/3/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    $BAND
    $BNFT
    $CHGG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Service Corporation International

    SC 13G - SERVICE CORP INTERNATIONAL (0000089089) (Subject)

    11/14/24 4:32:16 PM ET
    $SCI
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Chegg Inc.

    SC 13G/A - CHEGG, INC (0001364954) (Subject)

    11/14/24 4:02:16 PM ET
    $CHGG
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by New York Times Company

    SC 13G/A - NEW YORK TIMES CO (0000071691) (Subject)

    11/14/24 1:28:29 PM ET
    $NYT
    Newspapers/Magazines
    Consumer Discretionary